There is no other way to describe the September jobs report…it was disappointing at best. The economy only added 142,000 jobs last month, which was well below expectations. According to a number of media reports, the stock market responded negatively to the news; which essentially reflects the uncertainty that investors have about economic stability across the globe.
It remains to be seen whether the market tremors will continue and whether they affect the record pace of mergers and acquisitions. In a number of our posts, we have highlighted that these transactions have garnered a great deal of interest.
For the pharmaceutical industry, the market drop may not have an effect on acquisitions. After all, it may extend the window of opportunity that many businesses depend on to make the most of their investment dollars. Many drug makers believe that acquiring another company is the best way to keep revenues going, since it is often cheaper to acquire the next highly profitable drug instead of developing it in house. As long as this philosophy continues to be cost effective, it is reasonable to believe that these transactions will continue.
While this may be the case with the pharmaceutical industry, the same reasoning may not apply to others. The counsel that comes from an experienced business law attorney can help business owners understand the legal and financial implications that can come with a strategic acquisition. The attorneys at Shulman, Hodges & Bastain can advise business owners on the due diligence, projections and implementation plans necessary to minimize risk and make the most of the acquisition.